1.38 USD
-0.01 (-0.72%)
1.36 USD
-0.02 (-1.45%)
Overall RANI gets a fundamental rating of 1 out of 10. We evaluated RANI against 190 industry peers in the Pharmaceuticals industry. RANI has a bad profitability rating. Also its financial health evaluation is rather negative. RANI does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- RANI had negative earnings in the past year.
- RANI had a negative operating cash flow in the past year.
- RANI had negative earnings in each of the past 5 years.
- RANI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -279.27%, RANI is doing worse than 92.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -279.27% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-56.31%
ROA(5y)-39.33%
ROE(3y)-617.95%
ROE(5y)-378.96%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for RANI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- RANI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for RANI has been increased compared to 1 year ago.
- The number of shares outstanding for RANI has been increased compared to 5 years ago.
- Compared to 1 year ago, RANI has a worse debt to assets ratio.
2.2 Solvency
- RANI has an Altman-Z score of -26.21. This is a bad value and indicates that RANI is not financially healthy and even has some risk of bankruptcy.
- With a Altman-Z score value of -26.21, RANI is not doing good in the industry: 87.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -26.21 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
- RANI has a Current Ratio of 0.26. This is a bad value and indicates that RANI is not financially healthy enough and could expect problems in meeting its short term obligations.
- RANI has a worse Current ratio (0.26) than 94.74% of its industry peers.
- A Quick Ratio of 0.26 indicates that RANI may have some problems paying its short term obligations.
- The Quick ratio of RANI (0.26) is worse than 93.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.26 | ||
| Quick Ratio | 0.26 |
3. Growth
3.1 Past
- RANI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.47%, which is quite impressive.
- Measured over the past years, RANI shows a small growth in Revenue. The Revenue has been growing by 0.96% on average per year.
EPS 1Y (TTM)25.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-27.7%
Revenue growth 5Y0.96%
Sales Q2Q%N/A
3.2 Future
- Based on estimates for the next years, RANI will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.47% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y56.7%
EPS Next 2Y31.92%
EPS Next 3Y20%
EPS Next 5Y9.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RANI. In the last year negative earnings were reported.
- Also next year RANI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- RANI's earnings are expected to grow with 20.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.92%
EPS Next 3Y20%
5. Dividend
5.1 Amount
- RANI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
RANI THERAPEUTICS HOLDINGS-A / RANI FAQ
Can you provide the ChartMill fundamental rating for RANI THERAPEUTICS HOLDINGS-A?
ChartMill assigns a fundamental rating of 1 / 10 to RANI.
What is the valuation status of RANI THERAPEUTICS HOLDINGS-A (RANI) stock?
ChartMill assigns a valuation rating of 1 / 10 to RANI THERAPEUTICS HOLDINGS-A (RANI). This can be considered as Overvalued.
Can you provide the profitability details for RANI THERAPEUTICS HOLDINGS-A?
RANI THERAPEUTICS HOLDINGS-A (RANI) has a profitability rating of 0 / 10.
Can you provide the financial health for RANI stock?
The financial health rating of RANI THERAPEUTICS HOLDINGS-A (RANI) is 0 / 10.